These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 17998817)
1. Detection of RASSF1A and RARbeta hypermethylation in serum DNA from breast cancer patients. Shukla S; Mirza S; Sharma G; Parshad R; Gupta SD; Ralhan R Epigenetics; 2006; 1(2):88-93. PubMed ID: 17998817 [TBL] [Abstract][Full Text] [Related]
2. Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients. Dulaimi E; Hillinck J; Ibanez de Caceres I; Al-Saleem T; Cairns P Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6189-93. PubMed ID: 15448006 [TBL] [Abstract][Full Text] [Related]
3. Epigenetic alterations by methylation of RASSF1A and DAPK1 promoter sequences in mammary carcinoma detected in extracellular tumor DNA. Ahmed IA; Pusch CM; Hamed T; Rashad H; Idris A; El-Fadle AA; Blin N Cancer Genet Cytogenet; 2010 Jun; 199(2):96-100. PubMed ID: 20471512 [TBL] [Abstract][Full Text] [Related]
4. DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma. Fackler MJ; McVeigh M; Evron E; Garrett E; Mehrotra J; Polyak K; Sukumar S; Argani P Int J Cancer; 2003 Dec; 107(6):970-5. PubMed ID: 14601057 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of promoter hypermethylation detection in serum as a diagnostic tool for breast carcinoma in Korean women. Kim JH; Shin MH; Kweon SS; Park MH; Yoon JH; Lee JS; Choi C; Fackler MJ; Sukumar S Gynecol Oncol; 2010 Aug; 118(2):176-81. PubMed ID: 20466412 [TBL] [Abstract][Full Text] [Related]
6. Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients. Mirza S; Sharma G; Prasad CP; Parshad R; Srivastava A; Gupta SD; Ralhan R Life Sci; 2007 Jul; 81(4):280-7. PubMed ID: 17599361 [TBL] [Abstract][Full Text] [Related]
7. Clinical significance of promoter hypermethylation of ERβ and RARβ2 in tumor and serum DNA in Indian breast cancer patients. Mirza S; Sharma G; Parshad R; Srivastava A; Gupta SD; Ralhan R Ann Surg Oncol; 2012 Sep; 19(9):3107-15. PubMed ID: 22451234 [TBL] [Abstract][Full Text] [Related]
8. Detection of aberrant promoter methylation of GSTP1, RASSF1A, and RARβ2 in serum DNA of patients with breast cancer by a newly established one-step methylation-specific PCR assay. Yamamoto N; Nakayama T; Kajita M; Miyake T; Iwamoto T; Kim SJ; Sakai A; Ishihara H; Tamaki Y; Noguchi S Breast Cancer Res Treat; 2012 Feb; 132(1):165-73. PubMed ID: 21594664 [TBL] [Abstract][Full Text] [Related]
9. Detection of breast cancer in nipple aspirate fluid by CpG island hypermethylation. Krassenstein R; Sauter E; Dulaimi E; Battagli C; Ehya H; Klein-Szanto A; Cairns P Clin Cancer Res; 2004 Jan; 10(1 Pt 1):28-32. PubMed ID: 14734448 [TBL] [Abstract][Full Text] [Related]
10. Associations of RASSF1A, RARβ, and CDH1 promoter hypermethylation with oral cancer risk: A PRISMA-compliant meta-analysis. Wen G; Wang H; Zhong Z Medicine (Baltimore); 2018 Mar; 97(11):e9971. PubMed ID: 29538221 [TBL] [Abstract][Full Text] [Related]
11. Promoter hypermethylation of p16INK4A, p14ARF, CyclinD2 and Slit2 in serum and tumor DNA from breast cancer patients. Sharma G; Mirza S; Prasad CP; Srivastava A; Gupta SD; Ralhan R Life Sci; 2007 Apr; 80(20):1873-81. PubMed ID: 17383681 [TBL] [Abstract][Full Text] [Related]
12. Aberrant methylation of RASSF1A is associated with poor survival in Tunisian breast cancer patients. Karray-Chouayekh S; Trifa F; Khabir A; Boujelbane N; Sellami-Boudawara T; Daoud J; Frikha M; Jlidi R; Gargouri A; Mokdad-Gargouri R J Cancer Res Clin Oncol; 2010 Feb; 136(2):203-10. PubMed ID: 19657672 [TBL] [Abstract][Full Text] [Related]
13. Allele loss and promoter hypermethylation of VHL, RAR-beta, RASSF1A, and FHIT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma. Kuroki T; Trapasso F; Yendamuri S; Matsuyama A; Alder H; Mori M; Croce CM Cancer Res; 2003 Jul; 63(13):3724-8. PubMed ID: 12839965 [TBL] [Abstract][Full Text] [Related]
14. Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients. Honorio S; Agathanggelou A; Schuermann M; Pankow W; Viacava P; Maher ER; Latif F Oncogene; 2003 Jan; 22(1):147-50. PubMed ID: 12527916 [TBL] [Abstract][Full Text] [Related]
15. RASSF1A and CDH1 hypermethylation as potential epimarkers in breast cancer. Sebova K; Zmetakova I; Bella V; Kajo K; Stankovicova I; Kajabova V; Krivulcik T; Lasabova Z; Tomka M; Galbavy S; Fridrichova I Cancer Biomark; 2011-2012; 10(1):13-26. PubMed ID: 22297548 [TBL] [Abstract][Full Text] [Related]
16. Methylation status and protein expression of RASSF1A in breast cancer patients. Hagrass HA; Pasha HF; Shaheen MA; Abdel Bary EH; Kassem R Mol Biol Rep; 2014 Jan; 41(1):57-65. PubMed ID: 24253900 [TBL] [Abstract][Full Text] [Related]
17. Association of folate and other one-carbon related nutrients with hypermethylation status and expression of RARB, BRCA1, and RASSF1A genes in breast cancer patients. Pirouzpanah S; Taleban FA; Mehdipour P; Atri M J Mol Med (Berl); 2015 Aug; 93(8):917-34. PubMed ID: 25805039 [TBL] [Abstract][Full Text] [Related]
18. Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patients. Sharma G; Mirza S; Parshad R; Srivastava A; Gupta SD; Pandya P; Ralhan R Life Sci; 2010 Jul; 87(3-4):83-91. PubMed ID: 20470789 [TBL] [Abstract][Full Text] [Related]
19. Quantitative promoter hypermethylation analysis of cancer-related genes in salivary gland carcinomas: comparison with methylation-specific PCR technique and clinical significance. Lee ES; Issa JP; Roberts DB; Williams MD; Weber RS; Kies MS; El-Naggar AK Clin Cancer Res; 2008 May; 14(9):2664-72. PubMed ID: 18451230 [TBL] [Abstract][Full Text] [Related]
20. Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis. Shinozaki M; Hoon DS; Giuliano AE; Hansen NM; Wang HJ; Turner R; Taback B Clin Cancer Res; 2005 Mar; 11(6):2156-62. PubMed ID: 15788661 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]